首页> 外文期刊>Biochemical Pharmacology >Cyclic nucleotide-dependent phosphodiesterases (PDEI) inhibition by muscarinic antagonists in bovine tracheal smooth muscle.
【24h】

Cyclic nucleotide-dependent phosphodiesterases (PDEI) inhibition by muscarinic antagonists in bovine tracheal smooth muscle.

机译:毒蕈碱拮抗剂在牛气管平滑肌中抑制环状核苷酸依赖性磷酸二酯酶(PDEI)。

获取原文
获取原文并翻译 | 示例
           

摘要

In bovine tracheal smooth muscle (TSM) strips, muscarinic antagonists (atropine, 4-DAMP, AFDX-116 and methoctramine) were able to increase simultaneously and a similar fashion the intracellular levels of cyclic nucleotides, with a cAMP/cGMP ratio higher than 2.0. These original pharmacological responses were time-and dose-dependent, exhibiting maximal values at 15 min, with a pEC(50) of 7.4 +/- 0.2 for atropine and 4-DAMP. These effects on cAMP and cGMP levels were similar to the ones obtained with isobutyl-methylxantine (IBMX, 10 microM), a non-selective cyclic nucleotide phosphodiesterase (PDE) inhibitor, suggesting the involvement of PDEs in these muscarinic antagonist responses. Neither, rolipram (10 microM), a specific PDEIV inhibitor, nor zaprinast (10 microM), a PDEV inhibitor, exhibited this "atropine-like" responses. Instead, atropine enhanced the increments of cAMP levels induced by rolipram and cGMP levels by zaprinast. However, vinpocetine (20 microM), a non-calmodulin dependent PDEIC inhibitor was able to mimic these muscarinic antagonist responses in intact smooth muscle strips. In addition, in cell free systems, muscarinic antagonists inhibited the membrane-bound PDEIC activity whereas soluble (cytosol) PDEIC activity was not affected by these muscarinic drugs. These results indicate that muscarinic antagonists acting possibly as inverse agonists on M(2)/M(3)mAChRs anchored to sarcolemma membranes can initiate a new signal transducing cascade leading to the PDEIC inhibition, which produced a simultaneous rise in both cAMP and cGMP intracellular levels in tracheal smooth muscle.
机译:在牛气管平滑肌(TSM)试纸条中,毒蕈碱拮抗剂(阿托品,4-DAMP,AFDX-116和甲基辛特拉明)能够同时以类似的方式增加环核苷酸的细胞内水平,而cAMP / cGMP比值大于2.0 。这些原始药理反应是时间和剂量依赖性的,在15分钟时显示最大值,阿托品和4-DAMP的pEC(50)为7.4 +/- 0.2。这些对cAMP和cGMP水平的影响与使用异丁基甲基黄嘌呤(IBMX,10 microM)(一种非选择性环状核苷酸磷酸二酯酶(PDE)抑制剂)获得的影响相似,表明PDEs参与了这些毒蕈碱拮抗剂反应。特定的PDEIV抑制剂rolipram(10 microM)和PDEV抑制剂za​​prinast(10 microM)均未表现出这种“阿托品样”反应。相反,阿托品增强了由咯利普兰诱导的cAMP水平的增加和由扎普利斯特引起的cGMP水平的增加。但是,非钙调蛋白依赖性PDEIC抑制剂长春西汀(20 microM)能够模拟完整平滑肌条中的这些毒蕈碱拮抗剂反应。另外,在无细胞系统中,毒蕈碱拮抗剂抑制膜结合的PDEIC活性,而可溶性(胞浆)PDEIC活性不受这些毒蕈碱药物的影响。这些结果表明毒蕈碱拮抗剂可能充当锚定在肌膜上的M(2)/ M(3)mAChRs的反向激动剂,可以引发新的信号转导级联反应,导致PDEIC抑制,从而导致细胞内cAMP和cGMP的同时升高气管平滑肌中的水平。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号